Detalles de la búsqueda
1.
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Lancet
; 403(10443): 2504-2519, 2024 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38795716
2.
Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis Suppurativa Symptom Questionnaire, and Hidradenitis Suppurativa Quality of Life Questionnaire.
Dermatology
; 240(1): 65-76, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37820596
3.
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
J Am Acad Dermatol
; 79(2): 266-276.e5, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29660425
4.
Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.
Gastroenterology
; 148(4): 740-750.e2, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25644096
5.
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis.
Dig Dis Sci
; 60(11): 3408-17, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26386854
6.
Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
JAMA Dermatol
; 159(6): 606-612, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37099284
7.
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
JAMA Dermatol
; 157(11): 1279-1288, 2021 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34406364
8.
Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users.
Subst Abuse Rehabil
; 3: 101-13, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-24474870
9.
Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
J Opioid Manag
; 8(5): 315-27, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23247908
10.
Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Clin Ther
; 34(7): 1601-12, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22717418
Resultados
1 -
10
de 10
1
Próxima >
>>